CDKN1B, encoding for the CDK inhibitor p27kip1, has been confirmed mutant in various cancers including breast24, prostate cancer25 and small intestine neuroendocrine tumors26, of which the mutation and copy number variation are associated with tumor aggressiveness27. Here, CDKN1B is linked to neoplasm.